Tsourapas Panagiotis sold 19,938 shares of COLGATE PALMOLIVE CO at $98.74 for −$1.97M on Nov 4, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
COO, CD, EMEA, APac, Skin
COO, CD, EMEA, APac, Skin
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,968,708.03Shares × reported price
Shares traded
19,938Common Stock
Price per share
$98.74Reported price. Read footnotes for ranges.
% of reported position traded
68.64%This security and ownership context
Holdings after
9,111Direct
Trade date
Nov 4, 2026Sell
Filed
Nov 6, 2026, 4:05 PM ET2-day reporting delay
Accession
0001225208-26-008752Code S · Transaction 394654
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 29,049 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 4, 2026Option exercise19,938$76.41$1,523,462.58Trade 394653
Nov 4, 2026Option exercise19,938$0.00$0Trade 394655
3 transaction rows in this filing. Joint filers share the same rows.

CL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −11%1w ago −5%1d ago −1.3%
Returns since7d +3.2%30d90d180d1y

Footnotes in full

F1: Exercise of stock options awarded under the issuer's incentive compensation plan. F2: Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3: Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.585 to $98.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: This amount includes 2,336 shares that were previously reported as directly beneficially owned. F5: Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2020 grant date.